AFP and neoplasm: To be specific, for patients with M1, only patients with a tumor size of 3–5 cm, tumor number of two to three, or AFP >400 μg/L would benefit from the combination therapy, whereas for patients with M2, the combination therapy would be recommended in those with a tumor size of 2–3 cm, one recurrent tumor, or AFP ≤400 μg/L.